MSD

NICE recommends MSD’s KEYTRUDA® (pembrolizumab) with chemoradiotherapy (external beam radiation therapy followed by brachytherapy) , within its marketing authorisation, as an option for untreated International Federation of Gynaecology and Obstetrics (FIGO) 2014 stages 3 to 4A locally advanced cervical cancer (LACC) in adults

LONDON, 25th June 2026 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK)) today welcomes news that the National Institute for Health and Care Excellence (NICE) has recommended the use of KEYTRUDA® (pembrolizumab), within its marketing authorisation, as an option for patients with untreated FIGO 2014 stage III-IVA locally advanced cervical...

908-740-4000